CRB Inverbío

Biocross, S.L. is a biotechnology company based in Boecillo, Spain, founded in 2005. The company specializes in developing blood tests aimed at diagnosing Alzheimer’s disease for neurologists. Its offerings include the ApoE4 blood marker assay, which employs chemical analysis to identify the presence of the ApoE4 protein in human blood plasma. Additionally, Biocross provides the AD Dementia test, a multi-parametric evaluation that quantifies various metabolites and proteins in plasma samples, and a Degenerative Dementia test that detects altered blood biomarkers in neurodegenerative patients.

Aglaris is developing an automated cell culture bioreactor for the mass production of human stem cells. Aglaris produces equipment to ensure cell and tissue culture is an easy, problem-free task. By automating and controlling the cell culture processes, we can obtain cells and tissues with sufficient quality to revitalize regenerative medicine and cell therapies. The technology used by our equipment is unique and is protected by international patents.

Iden Biotechnology is a scientific enterprise based in Noain, Spain, focused on developing and commercializing innovative biotechnological solutions. The company specializes in plant-based technologies aimed at enhancing crop traits, increasing starch content and yield, improving nutritional profiles, and promoting stress tolerance. It also creates growth enhancers and fortifiers for various crops, alongside technologies that valorize byproducts from the biofuel industry into valuable compounds. Additionally, Iden Biotechnology offers protein purification technology utilizing enhanced protein-producing plant lines. The company provides research and development services, including plant genetic modification, plant culture infrastructure, and analytical services, catering to the agri-food, agrobiochemical, pharmaceutical, and energy sectors. Furthermore, Iden engages in R&D management, technology scouting, and intellectual property brokering, emphasizing the transfer of quality technology from academic research to industrial applications. Established in 2005, Iden Biotechnology aims to bridge the gap between market needs and biotechnological advancements.

Mecwins S.L. is a Spanish company based in Tres Cantos that specializes in nanotechnological solutions aimed at researchers across various scientific fields. Founded in 2008, the company has developed the SCALA platform, an ultrasensitive technology that characterizes mechanical-based sensor devices such as cantilevers and membranes in diverse environments including air, liquid, and vacuum. The SCALA platform features modules for dynamics, liquid measurement, and 3D imaging, enabling applications in biochip development, MEMS monitoring, biomedicine, drug discovery, and environmental analysis. Mecwins also produces ultra-high sensitive immunoassays targeting oncology, cardiovascular, and infectious diseases, serving researchers in materials science, biochemistry, medical diagnostics, and food science through its representatives in Spain.

Nuubo is a Spanish medical device company that designs, manufactures, and sells wearable wireless technologies aimed at monitoring cardiac health for prevention, diagnosis, and rehabilitation. The company's flagship product, the nECG DYNAMIC PLATFORM, consists of three components: a biomedical garment that captures electrocardiogram (ECG) signals without disrupting daily activities, a wireless device that continuously records and transmits this data, and analysis software that utilizes artificial intelligence for interpretation. Nuubo's solutions enable real-time ECG monitoring, allowing for longer monitoring periods while ensuring patient comfort. The company primarily serves professional sports teams and hospitals and has been operational since its founding in 2005, with its headquarters located in Madrid, Spain.

Ray Techniques Ltd. is engaged in the fabrication of nano-diamonds (ND) and ND compounds by an innovative technology.

Amadix is focused on developing and commercializing innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company's flagship product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis, aimed at reducing the high mortality rate associated with colon cancer. Amadix's approach emphasizes early detection, allowing for timely treatment while avoiding the complications of invasive procedures like tumor biopsies. The team comprises industry veterans with extensive expertise in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. Amadix's products undergo rigorous analytical validation and clinical studies before being introduced to the global market.

Health In Code, S.L. provides genetic diagnosis of familial cardiac diseases. It offers molecular genetic diagnostic services for the prognosis and therapeutic treatment in the field of hereditary cardiomyopathies, including hypertrophic and dilated cardiomyopathy, left ventricular non-compaction, arrhythmogenic right ventricle cardiomyopathy, and brugada and long QT syndrome, as well as channelopaties. The company also engages in the development of databases adapted to each pathology, including clinical and genetic information; and production of the corresponding reports to enable clinics to carry out individualised medicine with the support of genetic diagnosis. Health In Code is based in A Coruña, Spain. As of February 18, 2020, Health In Code, S.L. operates as a subsidiary of Alantra Private Equity.

Oncovision, a Spanish technology start-up established in 2003, specializes in developing medical imaging devices aimed at enhancing cancer diagnosis and treatment. The company focuses on Molecular Vision applied to health sciences, particularly in oncology, neurology, and cardiology. By creating innovative diagnostic tests and multimodal imaging technologies, Oncovision provides healthcare professionals with tools that offer clinical and economic advantages, ultimately improving patient quality of life. The company has garnered recognition for its original technologies and strong intellectual property, receiving accolades from prestigious Spanish and European institutions. Its team, composed of scientists, technicians, and technologists, has contributed to numerous publications and presentations at global medical conferences. Oncovision's advancements in imaging technology position it as a leader in the Spanish and European health industries, with a commitment to pioneering new standards in cancer treatment and care.

TCD Pharma, established in 2005, is a biotechnology company based in Spain that focuses on developing innovative therapies for oncology, particularly targeting unmet medical needs. The company's lead product, TCD-717, is currently in clinical trials. TCD Pharma aims to position itself as a key partner in oncology drug discovery and development by building its pipeline through in-licensing and strategic partnerships. The firm collaborates with premier Contract Research Organizations to leverage resources, significantly reducing the risks and costs associated with drug development. TCD Pharma's drug development center plays a critical role in advancing cancer treatments by providing enzymes that regulate phosphatidylcholine production, essential for cell membrane formation and proliferation. Through its strategic initiatives, TCD Pharma is dedicated to enhancing patient access to effective oncology therapies.

TCD Pharma, established in 2005, is a biotechnology company based in Spain that focuses on developing innovative therapies for oncology, particularly targeting unmet medical needs. The company's lead product, TCD-717, is currently in clinical trials. TCD Pharma aims to position itself as a key partner in oncology drug discovery and development by building its pipeline through in-licensing and strategic partnerships. The firm collaborates with premier Contract Research Organizations to leverage resources, significantly reducing the risks and costs associated with drug development. TCD Pharma's drug development center plays a critical role in advancing cancer treatments by providing enzymes that regulate phosphatidylcholine production, essential for cell membrane formation and proliferation. Through its strategic initiatives, TCD Pharma is dedicated to enhancing patient access to effective oncology therapies.